Justin C. Dodson

Array ( [id] => 20391809 [patent_doc_number] => 20250367284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/304134 [patent_app_country] => US [patent_app_date] => 2025-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19304134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20518740 [patent_doc_number] => 20260042844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-12 [patent_title] => APPLICATION OF ITIH1 IN PREPARATION OF DRUG FOR TREATMENT OF HEPATOCELLULAR CARCINOMA [patent_app_type] => utility [patent_app_number] => 19/292946 [patent_app_country] => US [patent_app_date] => 2025-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19292946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20407393 [patent_doc_number] => 20250376502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => IG-LIKE FUSION PROTEINS FOR TREATING GRAVES DISEASE [patent_app_type] => utility [patent_app_number] => 19/218323 [patent_app_country] => US [patent_app_date] => 2025-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19218323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658546 [patent_doc_number] => 20240425611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => Trispecific T cell Engagers [patent_app_type] => utility [patent_app_number] => 18/758038 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510613 [patent_doc_number] => 20240342299 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => STEROIDS AND ANTIBODY-CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 18/670314 [patent_app_country] => US [patent_app_date] => 2024-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19799029 [patent_doc_number] => 20250064954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => STEROIDS AND ANTIBODY-CONJUGATES THEREOF [patent_app_type] => utility [patent_app_number] => 18/670301 [patent_app_country] => US [patent_app_date] => 2024-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18670301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543199 [patent_doc_number] => 20240360235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 18/628224 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31345 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556754 [patent_doc_number] => 20240368546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors [patent_app_type] => utility [patent_app_number] => 18/622066 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18622066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20608350 [patent_doc_number] => 12583939 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Bispecific antigen binding molecules that bind HER2, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/600481 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 27 [patent_no_of_words] => 30560 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19305238 [patent_doc_number] => 20240233818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/442857 [patent_app_country] => US [patent_app_date] => 2024-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18442857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265391 [patent_doc_number] => 20240209090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER [patent_app_type] => utility [patent_app_number] => 18/425027 [patent_app_country] => US [patent_app_date] => 2024-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19614994 [patent_doc_number] => 20240400674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/545890 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157745 [patent_doc_number] => 20240150452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/532395 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003662 [patent_doc_number] => 20240067733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS [patent_app_type] => utility [patent_app_number] => 18/480778 [patent_app_country] => US [patent_app_date] => 2023-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18480778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067250 [patent_doc_number] => 20240101676 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => THE NOVEL MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) [patent_app_type] => utility [patent_app_number] => 18/459236 [patent_app_country] => US [patent_app_date] => 2023-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300005 [patent_doc_number] => 20240228574 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/452972 [patent_app_country] => US [patent_app_date] => 2023-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300005 [patent_doc_number] => 20240228574 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/452972 [patent_app_country] => US [patent_app_date] => 2023-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786481 [patent_doc_number] => 20230374609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => HLA-J AND MEDICAL/DIAGNOSTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/364409 [patent_app_country] => US [patent_app_date] => 2023-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895230 [patent_doc_number] => 20240010715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/357966 [patent_app_country] => US [patent_app_date] => 2023-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18357966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065625 [patent_doc_number] => 20240100051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Anti-Tumor Immunotherapy Enhancer [patent_app_type] => utility [patent_app_number] => 18/357366 [patent_app_country] => US [patent_app_date] => 2023-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18357366 [rel_patent_id] =>[rel_patent_doc_number] =>)